# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatm...
D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.
Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and PreventionComprehensive Re...
HC Wainwright & Co. analyst Yi Chen reiterates Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $7 price target.
- SEC Filing
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0...
D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.
Continue to observe a positive safety profile—no dose limiting toxicities, cytokinerelease syndrome or immune effector cell-ass...